M
$ Value
$0
Shares
70,000
Price
$0
Filed
Mar 30
Insider
Name
Fitzgerald Meghan
Title
—
CIK
0001349297
Roles
Director
Transaction Details
Transaction Date
2026-03-26
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
48,578
Footnotes
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.32 to $27.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. | Award of stock options to purchase Common Shares that is fully vested.
Filing Info
Fitzgerald Meghan's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-26 | ROIV | M | $616K |
| 2026-03-26 | ROIV | ▼ | $1.9M |
| 2026-03-26 | ROIV | M | $0 |
| 2025-05-23 | THC | M | — |
| 2025-05-23 | THC | D | $92K |
| 2025-05-23 | THC | M | — |
| 2025-05-22 | THC | A | $0 |
Other Insiders at ROIV (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MOMTAZEE JAMES C | — | — | 2026-04-17 |
| Fitzgerald Meghan | — | $1.9M | 2026-03-26 |
| Oren Ilan | — | — | 2026-04-17 |
|
Torti Frank
President and Vant Chair
|
— | — | 2026-03-31 |
|
Sukhatme Mayukh
President & CIO
|
— | — | 2026-03-31 |
|
Gline Matthew
CEO
|
— | $8.4M | 2026-04-16 |
|
Venker Eric
President & Immunovant CEO
|
— | $5.9M | 2026-04-20 |
| Epperly Melissa B, | — | — | 2026-04-17 |
|
Pulik Richard
CFO
|
— | — | 2026-04-20 |
|
Humes Jennifer
Chief Accounting Officer
|
— | $384K | 2026-04-20 |